F-star

From Wikipedia, the free encyclopedia

Script error: No such module "For".

Page Module:Infobox/styles.css has no content.Page Template:Infobox company/styles.css has no content.

F-star Biotechnology Ltd.
ISINScript error: No such module "WikidataIB".
IndustryScript error: No such module "WikidataIB".
PredecessorScript error: No such module "WikidataIB".
IncorporatedScript error: No such module "WikidataIB".
FoundedScript error: No such module "WikidataIB".
FounderScript error: No such module "WikidataIB".
DefunctScript error: No such module "WikidataIB".
SuccessorScript error: No such module "WikidataIB".
HeadquartersCambridge, UK
RevenueScript error: No such module "WikidataIB".
Script error: No such module "WikidataIB".
Script error: No such module "WikidataIB".
Total assetsScript error: No such module "WikidataIB".
Number of employees
Script error: No such module "WikidataIB".
ParentScript error: No such module "WikidataIB".
Websitewww.f-star.com

Script error: No such module "Check for conflicting parameters".Script error: No such module "Check for deprecated parameters".

F-star Biotechnology Ltd. was a biotechnology company, founded in Vienna in 2006,[1] with a former main research site in Cambridge, UK. The company was focused on developing bispecific monoclonal antibodies using a modular combinatorial approach that engineers the Fc constant region of an immunoglobulin into a novel antigen-binding site.[2][3]

References

Page Template:Reflist/styles.css has no content.

  1. ^ Page Module:Citation/CS1/styles.css has no content."F-star starts its operations" (PDF). F-Star. 12 June 2006. Retrieved 12 December 2016.
  2. ^ Page Module:Citation/CS1/styles.css has no content."Home". f-star.com.
  3. ^ Page Module:Citation/CS1/styles.css has no content.Wozniak-Knopp G, Bartl S, Bauer A, Mostageer M, Woisetschläger M, Antes B, Ettl K, Kainer M, Weberhofer G, Wiederkum S, Himmler G, Mudde GC, Rüker F (2010). "Introducing antigen-binding sites in structural loops of immunoglobulin constant domains: Fc fragments with engineered HER2/neu-binding sites and antibody properties". Protein Eng Des. 23 (4): 289–297. doi:10.1093/protein/gzq005. PMID 20150180.